Dividend Sensei (Adam Galas) is an Army veteran and stock analyst with 20+ years of market experience. He is a founding author of the investing group The Dividend Kings which focuses on helping ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), with a price target of $4.00. The company’s ...